Complement-mediated Renal Diseases

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Complement-mediated Renal Diseases trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 3 trials

RecruitingPhase 2

NCT07522099

Chinese Adults With Kidney Disease

This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases…

China30 participantsStarted 2026-07-23

Treatment: ADX-038, Telitacicept

RecruitingPhase 2

NCT06989359

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kid…

United States45 participantsStarted 2025-08-28

Treatment: ADX-038 Dose Level 2, ADX-038 Dose Level 1

RecruitingPhase 1

NCT07462780

A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants

This study is a first-in-human (FIH) trial of CMS-D017 conducted in healthy Chinese adult participants, consisting of two parts: Part 1-a single ascending dose…

China88 participantsStarted 2026-03-05

Treatment: CMS-D017 Capsule, CMS-D017 Placebo Capsule

All recent trials (15 shown)

CompletedPhase 1/2

NCT05083364

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patie…

Australia, Georgia, Germany62 participantsStarted 2022-02-01

Treatment: ARO-C3, Placebo

Active — Not RecruitingNot Applicable

NCT05985122

New Analytic Tools for aHUS and C3G Diagnosis

This protocol is part of a larger project, COMPRare (COMPlement-mediated Rare kidney diseases), which has been financed on behalf of the EJP RD (European Joint…

Italy180 participantsStarted 2023-07-01

Treatment: C3NEF assay

Complement-mediated Renal Diseases

Trial phase breakdown

Trial status

Actively recruiting — 3 trials

Chinese Adults With Kidney Disease

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants

All recent trials (15 shown)

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

New Analytic Tools for aHUS and C3G Diagnosis

Trial phase breakdown

Trial status

Actively recruiting — 3 trials

Chinese Adults With Kidney Disease

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants

All recent trials (15 shown)

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

New Analytic Tools for aHUS and C3G Diagnosis

Study of ARO-CFB in Adult Healthy Volunteers

Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease

CHART-C3G/CLNP023B12011

A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers